Literature DB >> 28466391

Mechanisms of HIV-1 Control.

Mary Soliman1, Geetha Srikrishna1, Ashwin Balagopal2.   

Abstract

PURPOSE OF REVIEW: HIV-1 infection is of global importance, and still incurs substantial morbidity and mortality. Although major pharmacologic advances over the past two decades have resulted in remarkable HIV-1 control, a cure is still forthcoming. One approach to a cure is to exploit natural mechanisms by which the host restricts HIV-1. Herein, we review past and recent discoveries of HIV-1 restriction factors, a diverse set of host proteins that limit HIV-1 replication at multiple levels, including entry, reverse transcription, integration, translation of viral proteins, and packaging and release of virions. RECENT
FINDINGS: Recent studies of intracellular HIV-1 restriction have offered unique molecular insights into HIV-1 replication and biology. Studies have revealed insights of how restriction factors drive HIV-1 evolution. Although HIV-1 restriction factors only partially control the virus, their importance is underscored by their effect on HIV-1 evolution and adaptation. The list of host restriction factors that control HIV-1 infection is likely to expand with future discoveries. A deeper understanding of the molecular mechanisms of regulation by these factors will uncover new targets for therapeutic control of HIV-1 infection.

Entities:  

Keywords:  HIV-1; Interferon; Interferon stimulated genes; Restriction factors

Mesh:

Year:  2017        PMID: 28466391      PMCID: PMC5983366          DOI: 10.1007/s11904-017-0357-9

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  94 in total

1.  Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

Authors:  David M Asmuth; Robert L Murphy; Susan L Rosenkranz; Juan J L Lertora; Shyam Kottilil; Yoninah Cramer; Ellen S Chan; Robert T Schooley; Charles R Rinaldo; Nathan Thielman; Xiao-Dong Li; Sharon M Wahl; Jessica Shore; Jennifer Janik; Richard A Lempicki; Yaa Simpson; Richard B Pollard
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

2.  TRIM5α-Mediated Ubiquitin Chain Conjugation Is Required for Inhibition of HIV-1 Reverse Transcription and Capsid Destabilization.

Authors:  Edward M Campbell; Jared Weingart; Paola Sette; Silvana Opp; Jaya Sastri; Sarah K O'Connor; Sarah Talley; Felipe Diaz-Griffero; Vanessa Hirsch; Fadila Bouamr
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

3.  Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Mol Interv       Date:  2009-04

4.  Unique features of TRIM5alpha among closely related human TRIM family members.

Authors:  Xing Li; Bert Gold; Colm O'hUigin; Felipe Diaz-Griffero; Byeongwoon Song; Zhihai Si; Yuan Li; Wen Yuan; Matthew Stremlau; Claudia Mische; Hassan Javanbakht; Mark Scally; Cheryl Winkler; Michael Dean; Joseph Sodroski
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

Review 5.  Innate immune sensing of HIV infection.

Authors:  Aymeric Silvin; Nicolas Manel
Journal:  Curr Opin Immunol       Date:  2015-01-24       Impact factor: 7.486

6.  Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.

Authors:  Sabine Kupzig; Viktor Korolchuk; Ruth Rollason; Anna Sugden; Andrew Wilde; George Banting
Journal:  Traffic       Date:  2003-10       Impact factor: 6.215

7.  The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB.

Authors:  Zhenlong Liu; Qinghua Pan; Zhibin Liang; Wentao Qiao; Shan Cen; Chen Liang
Journal:  Retrovirology       Date:  2015-01-09       Impact factor: 4.602

8.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

9.  Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.

Authors:  Caroline Goujon; Olivier Moncorgé; Hélène Bauby; Tomas Doyle; Christopher C Ward; Torsten Schaller; Stéphane Hué; Wendy S Barclay; Reiner Schulz; Michael H Malim
Journal:  Nature       Date:  2013-09-18       Impact factor: 49.962

10.  Expression profile of host restriction factors in HIV-1 elite controllers.

Authors:  Mohamed Abdel-Mohsen; Rui André Saraiva Raposo; Xutao Deng; Manqing Li; Teri Liegler; Elizabeth Sinclair; Mohamed S Salama; Hussam El-Din A Ghanem; Rebecca Hoh; Joseph K Wong; Michael David; Douglas F Nixon; Steven G Deeks; Satish K Pillai
Journal:  Retrovirology       Date:  2013-10-16       Impact factor: 4.602

View more
  3 in total

1.  Recognition of HIV-1 capsid by PQBP1 licenses an innate immune sensing of nascent HIV-1 DNA.

Authors:  Sunnie M Yoh; João I Mamede; Derrick Lau; Narae Ahn; Maria T Sánchez-Aparicio; Joshua Temple; Andrew Tuckwell; Nina V Fuchs; Gianguido C Cianci; Laura Riva; Heather Curry; Xin Yin; Stéphanie Gambut; Lacy M Simons; Judd F Hultquist; Renate König; Yong Xiong; Adolfo García-Sastre; Till Böcking; Thomas J Hope; Sumit K Chanda
Journal:  Mol Cell       Date:  2022-07-08       Impact factor: 19.328

Review 2.  The Battle of RNA Synthesis: Virus versus Host.

Authors:  Alex Harwig; Robert Landick; Ben Berkhout
Journal:  Viruses       Date:  2017-10-21       Impact factor: 5.048

Review 3.  The Complex Relationship between HTLV-1 and Nonsense-Mediated mRNA Decay (NMD).

Authors:  Léa Prochasson; Pierre Jalinot; Vincent Mocquet
Journal:  Pathogens       Date:  2020-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.